[SCHEDULE 13G/A] Xilio Therapeutics, Inc. SEC Filing
Gilead Sciences, Inc. reports beneficial ownership of 10,613,944 shares of Xilio Therapeutics, representing 19.9% of the outstanding common stock based on 51,827,910 shares outstanding. The filing states Gilead has sole voting and dispositive power over these shares. The holdings consist of 6,860,223 shares issued March 28, 2024; 485,250 shares issued April 3, 2024; 1,759,978 shares issued December 18, 2024; and 1,508,493 shares issuable upon exercise of pre-funded warrants. The statement certifies the shares were not acquired to change or influence control of the issuer.
Gilead Sciences, Inc. dichiara la propriet脿 effettiva di 10.613.944 azioni di Xilio Therapeutics, pari al 19,9% del capitale sociale in circolazione calcolato su 51.827.910 azioni. La comunicazione precisa che Gilead detiene il pieno potere di voto e di disposizione su tali azioni. Le partecipazioni includono 6.860.223 azioni emesse il 28 marzo 2024; 485.250 azioni emesse il 3 aprile 2024; 1.759.978 azioni emesse il 18 dicembre 2024; e 1.508.493 azioni esercitabili mediante warrant prefinanziati. La dichiarazione certifica che le azioni non sono state acquisite con l'intento di modificare o influenzare il controllo dell'emittente.
Gilead Sciences, Inc. informa de la propiedad beneficiaria de 10.613.944 acciones de Xilio Therapeutics, que representan el 19,9% del capital social en circulaci贸n sobre un total de 51.827.910 acciones. La presentaci贸n indica que Gilead tiene el poder exclusivo de voto y disposici贸n sobre estas acciones. Las participaciones comprenden 6.860.223 acciones emitidas el 28 de marzo de 2024; 485.250 acciones emitidas el 3 de abril de 2024; 1.759.978 acciones emitidas el 18 de diciembre de 2024; y 1.508.493 acciones susceptibles de emitirse mediante el ejercicio de warrants prefundados. La declaraci贸n certifica que las acciones no fueron adquiridas para cambiar o influir en el control del emisor.
Gilead Sciences, Inc.電� Xilio Therapeutics鞚� 欤检嫕 10,613,944欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 氚滍枆欤检嫕 齑� 51,827,910欤� 旮办鞙茧 19.9%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖 靹滊電� Gilead臧� 頃措嫻 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳 甓岉暅鞚� 氤挫湢頃橁碃 鞛堨潓鞚� 氇呾嫓頃╇媹雼�. 氤挫湢 雮挫棴鞚� 2024雲� 3鞗� 28鞚� 氚滍枆霅� 6,860,223欤�, 2024雲� 4鞗� 3鞚� 氚滍枆霅� 485,250欤�, 2024雲� 12鞗� 18鞚� 氚滍枆霅� 1,759,978欤�, 攴鸽Μ瓿� 靹犾旮� 鞗岆煱韸� 頄夓偓搿� 氚滍枆 臧�電ロ暅 1,508,493欤茧 甑劚霅╇媹雼�. 靹彪獏靹滊姅 頃措嫻 欤检嫕鞚� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頃╇媹雼�.
Gilead Sciences, Inc. d茅clare la propri茅t茅 b茅n茅ficiaire de 10 613 944 actions de Xilio Therapeutics, repr茅sentant 19,9% du capital social en circulation sur la base de 51 827 910 actions en circulation. Le dossier pr茅cise que Gilead d茅tient le pouvoir exclusif de vote et de disposition sur ces actions. Les avoirs se composent de 6 860 223 actions 茅mises le 28 mars 2024 ; 485 250 actions 茅mises le 3 avril 2024 ; 1 759 978 actions 茅mises le 18 d茅cembre 2024 ; et 1 508 493 actions pouvant 锚tre 茅mises par l'exercice de bons de souscription pr茅financ茅s. La d茅claration certifie que les actions n'ont pas 茅t茅 acquises dans le but de changer ou d'influencer le contr么le de l'茅metteur.
Gilead Sciences, Inc. meldet wirtschaftliches Eigentum an 10.613.944 Aktien von Xilio Therapeutics, was 19,9% des ausstehenden Stammkapitals auf Basis von 51.827.910 ausstehenden Aktien entspricht. Die Meldung besagt, dass Gilead alleinigen Stimm鈥� und Verf眉gungsgewalt 眉ber diese Aktien hat. Das Bestandspaket umfasst 6.860.223 Aktien ausgegeben am 28. M盲rz 2024; 485.250 Aktien ausgegeben am 3. April 2024; 1.759.978 Aktien ausgegeben am 18. Dezember 2024; sowie 1.508.493 Aktien, die durch Aus眉bung vorausfinanzierter Warrants ausgegeben werden k枚nnen. Die Erkl盲rung best盲tigt, dass die Aktien nicht erworben wurden, um die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen.
- Material, disclosed stake: Gilead reports 10,613,944 shares (19.9%) with full sole voting and dispositive power
- Transparent breakdown: Holdings detailed by issuance dates and include 1,508,493 shares from pre-funded warrants
- Compliance: Filing includes certification that the position is not intended to influence control, consistent with Schedule 13G treatment
- None.
Insights
TL;DR: A sizable strategic stake: 19.9% ownership with sole voting power could influence Xilio's valuation and strategic options.
Gilead's reported 10.6 million-share position equals just under 20% of Xilio's 51.8 million diluted shares, giving Gilead significant economic exposure and full voting control of that block. The breakdown shows multiple issuances and pre-funded warrants, indicating the position arose from discrete financing or transaction events rather than open-market accumulation. The filing's certification that the stake is not held to change control is legally significant but investors will likely monitor any engagement or board influence given the stake's scale.
TL;DR: Near-20% stake triggers governance scrutiny without automatic change-of-control disclosure; Gilead retains full voting/dispositive rights over its shares.
The 19.9% threshold is notable because it falls just below the 20% mark that often prompts additional regulatory and disclosure considerations; nevertheless, sole voting authority over the entire position makes Gilead a material shareholder for governance matters. The filing disclaims acquisition intent to influence control, which preserves Schedule 13G treatment, but stakeholders should expect potential engagement on strategic, licensing, or board matters given Gilead's profile and the stake's size.
Gilead Sciences, Inc. dichiara la propriet脿 effettiva di 10.613.944 azioni di Xilio Therapeutics, pari al 19,9% del capitale sociale in circolazione calcolato su 51.827.910 azioni. La comunicazione precisa che Gilead detiene il pieno potere di voto e di disposizione su tali azioni. Le partecipazioni includono 6.860.223 azioni emesse il 28 marzo 2024; 485.250 azioni emesse il 3 aprile 2024; 1.759.978 azioni emesse il 18 dicembre 2024; e 1.508.493 azioni esercitabili mediante warrant prefinanziati. La dichiarazione certifica che le azioni non sono state acquisite con l'intento di modificare o influenzare il controllo dell'emittente.
Gilead Sciences, Inc. informa de la propiedad beneficiaria de 10.613.944 acciones de Xilio Therapeutics, que representan el 19,9% del capital social en circulaci贸n sobre un total de 51.827.910 acciones. La presentaci贸n indica que Gilead tiene el poder exclusivo de voto y disposici贸n sobre estas acciones. Las participaciones comprenden 6.860.223 acciones emitidas el 28 de marzo de 2024; 485.250 acciones emitidas el 3 de abril de 2024; 1.759.978 acciones emitidas el 18 de diciembre de 2024; y 1.508.493 acciones susceptibles de emitirse mediante el ejercicio de warrants prefundados. La declaraci贸n certifica que las acciones no fueron adquiridas para cambiar o influir en el control del emisor.
Gilead Sciences, Inc.電� Xilio Therapeutics鞚� 欤检嫕 10,613,944欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 氚滍枆欤检嫕 齑� 51,827,910欤� 旮办鞙茧 19.9%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖 靹滊電� Gilead臧� 頃措嫻 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳 甓岉暅鞚� 氤挫湢頃橁碃 鞛堨潓鞚� 氇呾嫓頃╇媹雼�. 氤挫湢 雮挫棴鞚� 2024雲� 3鞗� 28鞚� 氚滍枆霅� 6,860,223欤�, 2024雲� 4鞗� 3鞚� 氚滍枆霅� 485,250欤�, 2024雲� 12鞗� 18鞚� 氚滍枆霅� 1,759,978欤�, 攴鸽Μ瓿� 靹犾旮� 鞗岆煱韸� 頄夓偓搿� 氚滍枆 臧�電ロ暅 1,508,493欤茧 甑劚霅╇媹雼�. 靹彪獏靹滊姅 頃措嫻 欤检嫕鞚� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頃╇媹雼�.
Gilead Sciences, Inc. d茅clare la propri茅t茅 b茅n茅ficiaire de 10 613 944 actions de Xilio Therapeutics, repr茅sentant 19,9% du capital social en circulation sur la base de 51 827 910 actions en circulation. Le dossier pr茅cise que Gilead d茅tient le pouvoir exclusif de vote et de disposition sur ces actions. Les avoirs se composent de 6 860 223 actions 茅mises le 28 mars 2024 ; 485 250 actions 茅mises le 3 avril 2024 ; 1 759 978 actions 茅mises le 18 d茅cembre 2024 ; et 1 508 493 actions pouvant 锚tre 茅mises par l'exercice de bons de souscription pr茅financ茅s. La d茅claration certifie que les actions n'ont pas 茅t茅 acquises dans le but de changer ou d'influencer le contr么le de l'茅metteur.
Gilead Sciences, Inc. meldet wirtschaftliches Eigentum an 10.613.944 Aktien von Xilio Therapeutics, was 19,9% des ausstehenden Stammkapitals auf Basis von 51.827.910 ausstehenden Aktien entspricht. Die Meldung besagt, dass Gilead alleinigen Stimm鈥� und Verf眉gungsgewalt 眉ber diese Aktien hat. Das Bestandspaket umfasst 6.860.223 Aktien ausgegeben am 28. M盲rz 2024; 485.250 Aktien ausgegeben am 3. April 2024; 1.759.978 Aktien ausgegeben am 18. Dezember 2024; sowie 1.508.493 Aktien, die durch Aus眉bung vorausfinanzierter Warrants ausgegeben werden k枚nnen. Die Erkl盲rung best盲tigt, dass die Aktien nicht erworben wurden, um die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen.
FAQ
How many Xilio Therapeutics (XLO) shares does Gilead own?
What percentage of Xilio (XLO) does Gilead's stake represent?
Does Gilead have voting control over its Xilio (XLO) shares?
How is Gilead's 10,613,944-share position composed?
Was Gilead's stake acquired to change or influence control of Xilio?
